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Abstract: Statin therapy in patients with cardiovascular disease is associated with reduced 
incidence of stroke. The Stroke Prevention by Aggressive Reduction of Cholesterol Levels 
(SPARCL) trial showed daily treatment with 80 mg of atorvastatin in patients with a recent 
stroke or transient ischemic attack (TIA) reduced the incidence of fatal or nonfatal stroke by 
16%. Several post hoc analyses of different subgroups followed the SPARCL study. They 
have not revealed any significant differences when patients were sorted by age, sex, presence 
of carotid disease or type of stroke, with the exception of intracranial hemorrhage as the entry 
event. Lower low-density lipoprotein cholesterol levels in addition to possible neuroprotective 
mechanisms due to atorvastatin treatment correlate with improved risk reduction. Although not 
predefined subgroups and subject to an insufficient power, these post hoc studies have gener-
ated new clinical questions. However, clinicians should avoid denying therapy based on such 
subgroup analysis. At this point, the best evidence powerfully demonstrates stroke and TIA 
patients should be prescribed high dose statin therapy for secondary stroke prevention.
Keywords: statins, intracranial hemorrhage, neuroprotection, outcome, prevention, carotid 
stenosis, transient ischemic attack
Introduction
Statins, as 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase inhibi-
tors, belong to a well established class of drugs that can reduce cholesterol, ameliorate 
vascular atherosclerosis and improve cardiovascular morbidity and mortality.1–5 Pre-
vious clinical trials demonstrated that statins reduce the first or recurrent stroke risk 
among patients with known heart disease and subsequently have become cornerstones 
of therapy for secondary prevention of vascular disease along with antiplatelets and 
antihypertensives.6 Among the statins atorvastatin is a synthetic type of HMG-CoA 
analogue that exhibits a substantial efficacy for decreasing total and low-density 
lipoprotein cholesterol (LDL-C) levels, triglycerides and modification of lipoprotein 
composition. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels 
(SPARCL) trial was the only study to test whether high doses of atorvastatin would 
reduce the risk of secondary stroke in patients with a previous stroke or transient 
ischemic attack (TIA) but without known heart disease.7 This paper will review the 
SPARCL trial, its sub group analyses, and related studies.
Mechanism of action
The beneficial effects of statins result, at least in part, from direct inhibition of 
HMG-CoA reductase.8 This inhibition reduces endogenous cholesterol biosynthesis Vascular Health and Risk Management 2010:6 230
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and increases the expression of LDL receptors responsible 
for LDL-C uptake and clearance.8 These do not seem to be 
the only mechanisms of action, and several other so-called 
“pleotropic” effects have been suggested.8 Those beneficial 
effects include modification of endothelial function, reduc-
tion of inflammatory responses, increase in plaque stabil-
ity, and inhibition of platelets with decreased thrombus 
formation. However, the neuroprotective mechanisms of 
statins against stroke are not well understood. Stroke animal 
models suggested that augmentation of cerebral blood flow 
by increasing nitric oxygen (NO) production, decrease of 
glutamate excitotoxicity, neurogenesis and angiogenesis are 
responsible for some of its neuroprotective actions.9–14 So far, 
the clinical importance of these nonlipid lowering properties 
remains uncertain.
The SPARCL trial
SPARCL was a prospective, double-blind, placebo-controlled 
international trial conducted at 205 centers, in which 
4731 patients with a history of stroke or TIA were random-
ized. Patients received either atorvastatin 80 mg per day 
(n = 2365) or placebo (n = 2366) and were followed for an 
average of 4.9 years.7 Stroke, or a TIA, was diagnosed by 
a neurologist within 30 days and randomization occurred 
within 1 to 6 months after the event. LDL-C concentration 
required being between 100 and 190 mg/dL, and any lipid-
altering treatments had to be discontinued 30 days before 
the first screening visit. Patients with hemorrhagic stroke 
were included only if they were believed to be at risk for 
ischemic stroke or coronary artery disease; patients with atrial 
fibrillation, cardiac sources of embolism and subarachnoid 
hemorrhage were excluded. The primary outcome was any 
nonfatal or fatal stroke after randomization. The analysis 
plan was prespecified and performed on an intention to 
treat basis with the inclusion of all patients who underwent 
randomization.
Demographics, mean LDL-C, stroke type, concomitant 
therapy, stroke risk factors and history of prior statin therapy 
were evenly distributed between placebo and treatment 
groups. The primary study endpoint, fatal or nonfatal stroke, 
was significantly less frequent in the atorvastatin group 
(11.2%) versus placebo (13.1%) and represented a relative 
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Figure 1 Kaplan-Meier curves for the first occurrence of primary endpoint (fatal or nonfatal stroke).
Reproduced with permission from The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient 
ischemic attack. N Engl J Med. 2006;355:549–559.7 Copyright © 2006 Massachusetts Medical Society.   All rights reserved.
Abbreviations: HR, hazard ratio; CI, confidence interval.Vascular Health and Risk Management 2010:6 231
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risk reduction (RRR) of 16% (P = 0.03, 95% confidence 
interval [CI]; 0.71–0.99) (Figure 1). Interestingly, this effect 
was driven predominately by reduced adjusted relative risk 
of fatal stroke which was decreased by 43% (P = 0.03), 
whereas atorvastatin had no significant effect on nonfatal 
stroke reduction (P = 0.11).7
Every secondary endpoint showed significant improvement 
with atorvastatin treatment: reduced relative risks of stroke 
and TIA (23%; P  0.001), TIA alone (26%; P = 0.004), 
major coronary events (35%; P = 0.003), nonfatal myocar-
dial infarction (49%; P = 0.001), major cardiovascular events 
(20%; P = 0.002), acute coronary events (35%; P = 0.001), 
any coronary events (42%; P  0.001), revascularization 
procedures (45%; P  0.001), and any cardiovascular event 
(26%; P  0.001).7 Total mortality (9.1% vs 8.9%), and cancer 
related mortality (2.4% vs 2.2%) did not significantly differ 
between groups.
After randomization, more patients in the placebo group 
withdrew consent (P = 0.07) or permanently stopped the 
study medication (P = 0.07). Approximately half as many 
atorvastatin (compared to placebo) recipients received open-
label statin therapy (11.4% vs 25.4%), and, in both study 
groups, atorvastatin was the most widely used nonstudy 
open-label statin.7 The use of open label statins reduced the 
frequency of strokes in the placebo group; therefore the over-
all effect size appeared to be smaller than it actually was.
In contrast to the reduction of ischemic stroke and TIA, 
there was a significant increase in the incidence of hemor-
rhagic stroke in the atorvastatin group (2.3% vs 1.4%). 
Regarding adverse effects, a benign but significant elevation 
of aspartate aminotransferase occurred in the treatment group 
but was not associated with liver failure or rhabdomyolisis. 
No other differences in adverse events and laboratory values 
were noted.
With a number needed to treat (NNT) of 143 patients 
to prevent one recurrent ischemic stroke per year, aspirin is 
considered a first line medical therapy for secondary stroke 
prevention.15 In comparison, the NNT with atorvastatin to 
prevent one stroke is 46 patients over 5 years and is likely 
much lower due to poor adherence in the treatment group. 
While the benefit of atorvastatin may not be apparent to 
every individual, it has an enormous impact when applied to 
an entire population. Furthermore, the reduction of cardiac 
and peripheral arterial disease in this group is important. In 
summary, SPARCL demonstrated that high dose atorvas-
tatin decreased the risk of secondary stroke, major coronary 
events and revascularization procedures among patients with 
a recent stroke or TIA.7
SPARCL subgroup analysis
Multiple publications consisting of subgroup analyses origi-
nated from SPARCL. Although not predefined in the original 
study and inadequately powered, these post hoc studies 
  suggest answers to important clinical questions, generate new 
hypothesis and strengthen (or weaken) previous theories of 
statin use in stroke patients. However, any subgroup analysis 
should be interpreted cautiously until further confirmatory 
studies are performed.
Intracranial hemorrhage (ICH)
Epidemiological and observational studies have shown a 
relationship between low cholesterol levels and hemor-
rhagic stroke but that difference was not found in trials 
with statins given for coronary artery disease.16–19 In 
SPARCL, the overall incidence of hemorrhagic stroke was 
low (1.8%).7 While mortality from hemorrhagic stroke 
was similar (17 in the atorvastatin vs 18 patients in the 
placebo group) there was a statistically significant differ-
ence between the two groups (2.3% in the atorvastatin vs 
1.4% in the placebo group; P = 0.01).7 Post hoc analyses 
based on stroke type revealed that atorvastatin reduced 
the relative risk of fatal and not fatal of ischemic stroke 
by 21% (P = 0.01); this effect was partially attenuated 
by an increased risk of hemorrhage (unadjusted hazard 
ratio [HR] 0.79, 95% CI 1.09–2.59) resulting in the 
overall reduction of 16% in the risk of fatal and nonfatal 
stroke.20 Interestingly, the risk of hemorrhagic stroke was 
not related to of LDL-C levels in statin-treated subjects. 
Using Cox multivariable regression analysis male sex, 
hypertension, advancing age and a hemorrhagic or small 
vessel stroke upon study entry were independent risk 
factors associated with hemorrhagic stroke.20 Treatment 
did not disproportionally increase the hemorrhage risk 
in these patients; conversely, those with hemorrhagic 
stroke at entry did not benefit from treatment (HR 2.82, 
95% CI 0.89–9.01).20 The SPARCL findings contradict 
several cardiac interventional studies using statins where 
increased intracranial hemorrhage was not found.1–4 In 
the Heart Protection Study, patients enrolled with prior 
history of stroke were found to have a nonsignificant 
increase in hemorrhagic stroke if treated with simvas-
tatin 40 mg per day compared with the placebo group.5 
Because most SPARCL patients had stroke as entry event 
(60.9%), it is possible that patients with prior cerebro-
vascular accident are prone to ICH after statin therapy. 
Based on the SPARCL data, it seems that patients with 
hemorrhagic stroke as an entry event may not benefit from Vascular Health and Risk Management 2010:6 232
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statin therapy. Most importantly though, as the authors 
conclude, the theoretical risk of ICH with high dose 
statins should be balanced with the compelling benefit 
of treatment that reduces the overall risk of stroke and 
other cardiovascular events.
LDL-C and outcome in SPARCL
LDL-C reduction was used as a marker for adherence to 
the allocated treatment and patients were subsequently 
classified into levels of LDL-C reduction. Based on 55,045 
blinded measures, patients with 50% reduction had a 
31% decrease in the combined risk of fatal and nonfatal 
stroke.21 This was approximately twice the 16% observed 
in the prespecified intention to treat analysis (Figure 2).7 
Additionally, increased ICH were not observed in the 
group with the greatest reduction of LDL-C.21 Only lower 
high-density lipoprotein cholesterol (HDL-C) levels at 
baseline predicted the risk of both, recurrent stroke and 
mayor cardiovascular events; however, high baseline levels 
of triglycerides and LDL/HDL ratio were associated to the 
occurrence of mayor cardiovascular events.22 In the treat-
ment group, higher HDL-C levels were maintained at low 
levels of LDL-C and a there was cumulative protective effect 
for major cardiovascular events and stroke when having all 
together, lower LDC-L, higher HDL-C and optimal blood 
pressure control.23 Although the intention to treat analysis 
is often the best way to determine treatment efficacy, this 
post hoc analysis using LDL-C levels as a surrogate of high 
dose atorvastatin, attempts to answer the initial SPARCL 
hypothesis disregarding noncompliance observed during 
trial. The findings are consistent with two previous meta-
analysis revealing an association between reduced stroke 
risk and reduction of LDL-C.6,24 However, because the 
relationship between stroke and cholesterol levels is not 
as clearly defined as for coronary artery disease, the dose-
related stroke risk reduction found in this analysis could 
be attributed to pleotropic effects and vascular protection 
rather than simple LDL-C reduction.
All atorvastatin patients
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Figure 2 Primary endpoint (fatal or nonfatal stroke) by different patient subgroups showing the treatment hazard ratios from the Cox regression model.
*Type of event at entry study.
Abbreviations: CS, carotid stenosis; CI, confidence interval; C-LDL, low-density lipoprotein cholesterol; TIA, transient ischemic attack.Vascular Health and Risk Management 2010:6 233
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Age and sex differences in SPARCL
Stroke is more frequent in individuals 65 years or older.25,26 
Several studies have shown the benefits of statin treatment in 
elderly patients, particularly those with established vascular 
disease or risk factors for it.5,27–30 Unfortunately, elderly 
patients are less likely to be prescribed statins, and have worse 
compliance compared to younger patients.31 An analysis of 
the entire SPARCL cohort , using an intention to treat pro-
tocol, compared primary and secondary endpoints between 
patients over 65 and under 65 years old.32 Patients over 65 
were more likely to have hypertension, a history of carotid 
stenosis at baseline, and less likely to be current smokers 
compared with younger patients.32 For the primary endpoint 
there was a 10% RRR (HR 0.90, 0.73–1.11, P = 0.33) in 
the elderly group compared to a 26% RRR in the younger 
group (HR 0.74, 0.57–0.96, P = 0.02).32 This corresponded 
to an absolute risk reduction of 1.5% in the elderly group 
and 2.6% in the younger group (Figure 2).32 A test of het-
erogeneity for a treatment–age interaction, however, was not 
significant (P = 0.52).32 There were no treatment interactions 
associated with age for the SPARCL primary endpoint or 
any of the SPARCL secondary endpoints.32 Atorvastatin 
was well tolerated in both groups, though serious adverse 
events were more common in the elderly with either active 
treatment or placebo.32 Significant elevation in liver enzymes 
and myopathy were uncommon with atorvastatin and equally 
reported in both the cohorts.32 Although the risk reduction 
with high dose statins was not significant for older patients, 
no interactions were found between age and treatment effect. 
The authors note the study was not powered for detecting risk 
reduction in older patients. Ultimately, all we can conclude 
is the findings suggest a possible benefit in stroke prevention 
in the elderly group.
Regarding gender, a secondary analysis of the effects of 
statin therapy in primary and secondary endpoints in men 
and women was also attempted.33 Although stroke risk factor 
profiles from the SPARCL baseline data differed for men and 
women, a secondary analysis did not find any differences in 
statin treatment effects or adverse reactions.33
SPARCL by stroke subtypes
Differences in outcomes between various stroke subtypes 
were also examined. Baseline stroke subtype assignment was 
based on local investigator judgment and not standardized 
or adjudicated. Neuroimaging data was not available for the 
final analysis but it was used by local investigators for the 
elucidation of stroke subtype. Among 4731 participants, 
4728 had information regarding entry event subtype with 
15.8% classified as having large vessel disease, 29.8% small 
vessel disease, 21.5% ischemic stroke of unknown cause, 
30.9% TIA, and 2% hemorrhagic stroke.34 Primary and 
secondary endpoints were obtained and no differences were 
found across baseline stroke subtypes with the exception of 
hemorrhagic stroke (Figure 2).34 This post hoc analysis was 
exploratory as it oversimplified stroke subtypes and lacked 
power for subgroup analyses. It contained an estimated a 
power of 51% to detect the risk reduction of 16% observed 
for the primary SPARCL end point between all entry event 
stroke subtypes. The power to detect a risk reduction of 16% 
was 20% for the small vessel disease group but only 6% for 
the hemorrhagic stroke group. Hence, a difference among 
ischemic stroke subtypes may exist but could not be proven 
by this subgroup analysis.
Atorvastatin and carotid disease
Carotid artery evaluation was not required by the SPARCL 
protocol, but 4278 (90.4%) of the SPARCL subjects under-
went carotid imaging by the local investigators at the time of 
patient randomization.35 3724 subjects did not have carotid 
stenosis while 1007 subjects had carotid stenosis, including 
453 subjects categorized as unknown carotid status.35 Within 
the carotid stenosis group, a primary end point occurred in 
55 patients randomized to atorvastatin and in 83 randomized 
to placebo.35 Patients with carotid stenosis randomized to ator-
vastatin reduced their risk of stroke by 33% (HR 0.67, 95% 
CI 0.47–0.94; P = 0.02) (Figure 2) and risk of TIA or stroke 
by 34% (HR 0.66, 95% CI 0.50–0.89; P = 0.005).35 Further-
more, all cardiovascular end points were reduced in patients 
with carotid stenosis treated with atorvastatin: major coronary 
events by 43% (HR 0.57, 95% CI 0.32–1.00; P = 0.05), any 
cardiovascular event by 42% (HR 0.58, 95% CI 0.46–0.73; 
P  0.0001), any revascularization procedure by 51% (HR 
0.49, 95% CI 0.33–0.73; P = 0.0004), and carotid revascular-
izations by 56% (HR 0.44, 95% CI 0.24–0.79; P = 0.006).35 
With the exception of carotid revascularization there was not 
heterogeneity regarding primary and secondary endpoints. 
However, the carotid stenosis group treated with atorvastatin 
had a higher absolute risk reduction and benefited more when 
all cardiovascular events were taken into consideration.35
The authors estimated a NNT of 20 patients treated for 
5 years to prevent one stroke using high dose atorvastatin 
in patients with carotid disease. Considering all cardiovas-
cular events, the annual risk reduction exceeded 2.5% per 
year estimating a NNT of 8 patients over 5 years. This is 
comparable to performing carotid endarterectomy in asymp-
tomatic patients but without the risks of surgery or additional Vascular Health and Risk Management 2010:6 234
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benefits of reduced cardiovascular events.36,37 This subanalysis 
suggested that patients with carotid disease receive the most 
benefit for secondary stroke prevention. This implies that 
statins powerfully modulate atherosclerotic disease and 
could, in theory, similarly benefit patients with aortic arch 
or intracranial stenosis.
Statin use and stroke outcome
There is ample laboratory data suggesting pleotropic effects 
of statins might not only affect the risk of stroke but also 
secondary stroke outcome.8 In the SPARCL trial a total of 
265 patients randomized to atorvastatin and 311 patients ran-
domized to placebo suffered a stroke.7 An exploratory analy-
sis of the trial assessed whether treatment favorably changed 
the distribution of stroke severities using the modified Rankin 
scale (mRS), National Institute of Health Stroke Scale 
(NISSS) and Bathel Index (BI) at enrollment and 90 days 
post stroke.38 Among all subjects having an ischemic stroke 
during the trial, there was a trend toward less severe outcomes 
in those taking atorvastatin based on the mRS in (P = 0.647) 
(Figure 3). This was true despite poor adherence to random-
ized treatments. No other differences were significant. The 
authors found a significant reduction of all stroke events and 
all ischemic events (P  0.001) using Mantel-Haenszel test 
after creating a composite of fatal stroke, severe (mRS 5-4), 
moderate (mRS 3-2), mild (mRS 1-0), TIA and no events.38 
However, this analysis combined stroke prevention and stroke 
“attenuation” properties making it inadequate for definitively 
determining a favorable outcome after a secondary stroke. 
Possible reduction in secondary stroke severity using statins 
has been suggested by observational studies but has yet to 
be proven.39–42 Interestingly, there is experimental animal43,44 
and human epidemiological data45,46 revealing that prior use 
of statins protects the brain and improves outcomes after 
intracranial hemorrhage. The latter was not replicated by 
the SPACRL trial.
Stroke as a coronary risk equivalent
During the 4.9 years of follow-up in SPARCL, patients with 
recent stroke or TIA had a 5.1% incidence of a major coronary 
event (death from cardiac causes [1.6%], nonfatal myocardial 
infarction [3.5%]), major cardiovascular event (17.2%), any 
coronary event (8.6%) and need for revascularization (coro-
nary, carotid or peripheral; 6.9%).7 High dose atorvastatin 
reduced major coronary events by 35% (HR 0.65,CI 95% 
0.49–0.87), any coronary event by 42% (HR 0.58, 95% CI 
0.46–0.73]) and the need for revascularization by 45% (HR 
0.55, 95% CI 0.43–0.72).7 The high incidence of coronary 
vascular events in patients with ischemic stroke, as well as 
the profound reduction of coronary events with statin treat-
ment, has caused stroke and TIA to be considered a coronary 
risk equivalent.47 SPARCL confirmed the high risk for non-
stroke vascular events and their substantial reduction with 
atorvastatin. Recent reviews of clinical trials illustrate this 
relationship and suggest the idea of adding cardiovascular 
endpoint events in preventive stroke clinical trials.48,49 Future 
studies should assess the use of cardiac screening test within 
ischemic stroke patients.
Conclusion
The SPARCL trial has shown that high dose atorvastatin is 
an effective medication for secondary prevention of stroke 
15% 31% 16% 16% 10% 5% 7%
18%
Placebo
N = 257
Atorvastatin
N = 197
mRS 1 mRS 2 mRS 3 mRS 4-6
33% 21% 14% 8% 2% 4%
mRS 0
Figure 3 Stroke severity after 90 days measured by modified Rankin Score (mRS) from subjects who had only ischemic stroke during the trial. P = 0.067 Using Cochran-
Mantel-Haenszel test.
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and cardiovascular events in patients with no known history 
of cardiac disease.7 Although treating patients with a history 
of ICH should be considered with caution, we feel it is inap-
propriate to deny an effective therapy to stroke patients based 
on subgroup analysis. Further studies might help to identify 
best responders and stratify risk groups.
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